SAINT: A Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission

ISGlobal researcher Carlos Chaccour presents, as principal investigator, the main findings of SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) which have been published in EClinicalMedicine, a clinical journal published by The Lancet. Chaccour and his team evaluated whether the maximal dose of ivermectin —an antiparasitic drug— recommended in Europe could have an impact on viral transmission when administered within the first days after symptom onset.